Protein expression and production teams in the pharmaceutical industry, CROs, and other protein service providers spend a lot of time and resources trying to identify the optimal conditions for high expression levels of recombinant protein. The process is generally tedious and inefficient, often driven by trial and error, especially for novel targets. It’s clear that knowing early on if a recombinant protein is not only highly expressed but also structurally stable would make protein production teams more efficient by lowering cost, providing actionable insights at the small-scale stage, and allowing faster hand-over of high-quality proteins to clients or teams downstream. This case study compares the evaluation of expression conditions of His-tagged HRV3C protease expressed in E.coli using data from traditional SDS-PAGE and the Andromeda system.
What you’ll learn It’s very common to experience low expression levels when producing membrane proteins — ...
Have a question about Andromeda?Contact Specialist
See more related content
Get more information about your protein expression conditions in less time with Andromeda
Poor expression levels, solubilization, and stability — these are the daily challenges that your membrane protein production team faces every day. You go through long cycles of expression optimization
What you’ll learn It’s very common to experience low expression levels when producing membrane proteins — plus they’re finicky and unstable when they're outside of their native environment. Just know
SOUTH SAN FRANCISCO, Calif. June 24, 2021 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, enters the protein production market with...